Evaluation of Ceftazidime/Avibactam Administration in Enterobacteriaceae and Pseudomonas aeruginosa Bloodstream Infections by Monte Carlo Simulation

References

• LealHF, AzevedoJ, SilvaGEO, et al. Bloodstream infections caused by multidrug-resistant gram-negative bacteria: epidemiological, clinical and microbiological features. BMC Infect Dis. 2019;19(1):609. doi:10.1186/s12879-019-4265-z31296179
   PubMed Web of Science ®Google Scholar
• AktaşZ, KayacanC, OnculO. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39(1):86–89. doi:10.1016/j.ijantimicag.2011.09.01222041508
   PubMed Web of Science ®Google Scholar
• LivermoreDM, MushtaqS, WarnerM, MiossecC, WoodfordN. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother. 2008;62(5):1053–1056. doi:10.1093/jac/dkn32018689875
   PubMed Web of Science ®Google Scholar
• CrandonJL, SchuckVJ, BaneviciusMA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(12):6137–6146. doi:10.1128/AAC.00851-1222985878
   PubMed Web of Science ®Google Scholar
• RobertsJA, KirkpatrickCM, LipmanJ. Monte carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2011;66(2):227–231. doi:10.1093/jac/dkq44921118912
   PubMed Web of Science ®Google Scholar
• SySK, ZhuangL, DerendorfH. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert Opin Drug Metab Toxicol. 2016;12(1):93–114. doi:10.1517/17425255.2016.112325026652832
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. 30th Edition. 2020. Available from: http://www.clsi.org/. Accessed 1, 2020.
   Google Scholar
• SteinGE, SmithCL, ScharmenA, et al. Pharmacokinetic and pharmacodynamic analysis of Ceftazidime/Avibactam in critically Ill patients. Surg Infect. 2019;20(1):55–61. doi:10.1089/sur.2018.141
   PubMed Web of Science ®Google Scholar
• KiddJM, SteinGE, NicolauDP, KutiJL. Monte carlo simulation methodologies for β-lactam/β-lactamase inhibitor combinations: effect on probability of target attainment assessments. J Clin Pharmacol. 2020;60(2):172–180. doi:10.1002/jcph.151031423601
   PubMed Web of Science ®Google Scholar
• ZasowskiEJ, RybakJM, RybakMJ. The β-Lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015;35(8):755–770. doi:10.1002/phar.162226289307
   PubMed Web of Science ®Google Scholar
• O’BrienJM, AliNA, AbereggSK, AbrahamE. Sepsis. Am J Med. 2007;120(12):1012–1022. doi:10.1016/j.amjmed.2007.01.03518060918
   PubMed Web of Science ®Google Scholar
• RhodesA, EvansLE, AlhazzaniW, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.28101605
   PubMed Web of Science ®Google Scholar
• SalmanovAG, VoronenkoYV, VozianovSO, et al. Bloodstream infections and antimicrobial resistance of responsible pathogens in Ukraine: results of a multicenter study (2013–2015). Wiad Lek. 2019;72(11 cz 1):2069–2075.31860848
   PubMedGoogle Scholar
• ZhanelGG, LawsonCD, AdamH, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159–177. doi:10.1007/s40265-013-0013-723371303
   PubMed Web of Science ®Google Scholar
• ZhangH, XuY, JiaP, et al. Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012–2016). Antimicrob Resist Infect Control. 2020;9(1):166. doi:10.1186/s13756-020-00829-z33109242
   PubMed Web of Science ®Google Scholar
• YinD, WuS, YangY, et al. Results from the China antimicrobial surveillance network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(4):e02431–18. doi:10.1128/AAC.02431-1830617091
   PubMed Web of Science ®Google Scholar
• TrangM, DudleyMN, BhavnaniSM. Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection. Curr Opin Pharmacol. 2017;36:107–113. doi:10.1016/j.coph.2017.09.00929128853
   PubMed Web of Science ®Google Scholar
• BensmanTJ, WangJ, JayneJ, et al. Pharmacokinetic-pharmacodynamic target attainment analyses to determine optimal dosing of ceftazidime-avibactam for the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Antimicrob Agents Chemother. 2017;61(10):e00988–17. doi:10.1128/AAC.00988-1728784670
   PubMed Web of Science ®Google Scholar